Press Enter to search · ESC to close

Macro

China NMPA Approves Ruifexibart Subcutaneous Injection for HoFH

China’s National Medical Products Administration approved ruifexibart injection (subcutaneous), marketed as Aiqingda, from Beijing Shengdi Pharmaceutical, for adults and adolescents aged 12 and older with homozygous familial hypercholesterolemia (HoFH). The drug, cleared under the priority review pathway, is used alongside a low-fat diet and other lipid-lowering therapies to reduce LDL-C levels, offering patients a new treatment option.

Share

Related News

Cointime share card
Long-press the image to save or share
Pitch us Community Feedback